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ABSTRACT OF THE DISSERTATION 
HPV16 E6* Induces Oxidative Stress and DNA Damage 
by 
Vonetta M. Williams 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, June 2014 
Dr. Penelope J. Duerksen-Hughes, Chairperson 
 
High risk types of Human Papillomavirus are the causative agents of virtually all 
cases of cervical cancer, 50-90% of other anogenital cancers and approximately 30% of 
oral and pharyngeal cancers. The high-risk types encode two viral oncogenes, E6 and E7, 
which work together to initiate cell transformation. The approximately 50 amino acid 
product of the E6* transcript is expressed during the early stages of HPV infection. In 
this study, we found that expression of E6* increased the level of reactive oxygen species 
(ROS) in both HPV+ and HPV- cells. This increased oxidative stress led to higher levels 
of DNA damage. The observed increase in ROS may be due to a decrease in cellular anti-
oxidant activity, as we found that E6* expression also led to decreased expression of 
SOD and Gpx, These studies indicate that E6* may play an important role in virus-
induced mutagenesis by increasing oxidative stress and DNA damage. 
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CHAPTER ONE 
INTRODUCTION 
 
The Human Papillomavirus (HPV), a double strand DNA virus, was first 
identified in skin cells in the 1950’s. They are now known to infect basal keratinocytes in 
the skin and mucosal membranes. They are the causative agents of diseases that affect 
both the cutaneous and mucosal epithelia, from common warts to invasive carcinoma. 
Harald zur Hausen, who received the 2008 Nobel Prize for his work, was the first to link 
HPV infection to cervical neoplasia  (zur Hausen, 1976). HPVs are divided into more 
than 100 different strains or types based on sequence differences within their L1 gene 
(Calleja-Macias et al., 2005). HPV types are designated “low-risk” or “high-risk”, based 
on whether they are known to cause benign or cancerous lesions (Ault, 2007). HPV 
infection is the most common sexually transmitted infection with an estimated point 
prevalence of about 43 to 62% (Giuliano et al., 2008; Hariri et al., 2011). High-risk HPV 
infections are asymptomatic and the vast majority of individuals infected with the virus 
will clear the infection without ever progressing to cervical cancer.  However, in some 
cases due to the presence of certain risk factors such as smoking, co-infection with other 
sexually transmitted diseases and immunologic deficiency the infection persists and may 
eventually lead to cancer. Current data provides evidence that HPV is responsible for a 
considerable health burden worldwide, as these viruses are involved in the etiology of a 
significant percentage of both anogenital (anal, penile, vaginal and vulvar) and 
oropharyngeal cancers. Approximately 4-5% of all cancers worldwide are associated with 
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HPV infection (Parkin & Bray, 2006).  High-risk oncogenic human papillomaviruses 
have been shown to be the etiological agents of cervical cancer, the second most common 
cancer in women worldwide, and virtually all cases of cervical cancer and anogenital 
cancer are caused by about 15 types of human papillomavirus (Guccione, Pim, & Banks, 
2004; Walboomers et al., 1999; Weaver, 2006). High-risk papillomaviruses DNA has 
now been detected in over 70% of cases of oropharyngeal cancer in patient samples 
collected in the US between 2000-2004 (Chaturvedi et al., 2011).  
While the incidence of cervical cancer in the US has declined dramatically 
(almost 75%) over the last several decades since the 1940’s due to better screening with 
the Pap smear and is expected to decrease even further with the widespread usage of the 
HPV vaccines, the same is not true for other HPV-related cancers (Scarinci et al., 2010). 
A 2014 review in Oral Oncology notes that there has been an increase over the last three 
decades in the incidence of squamous cell carcinoma of the oropharynx as a result not of 
smoking but rather HPV infection (Pytynia, Dahlstrom, & Sturgis, 2014). Additionally, 
the incidence of HPV-related anal cancer has been increasing steadily in both men and 
women over the last few decades with an exponential increase particularly among the 
men who have sex with men (MSM) group (Frisch, 2002).  
The high-risk strains HPV-16, HPV-18, HPV 45 and HPV-31 together are 
responsible for the majority of cases of cervical cancer, with HPV-16 responsible for 
almost 60% alone (Muñoz et al., 2003). Even with recent advances in the sequencing of 
HPV genomes, details of viral gene expression and regulation remain incomplete. 
Therefore, there remains a need to explore the mechanisms of HPV-associated cancer 
3 
progression, and in particular, the incompletely understood process of HR-HPV 
integration. 
 
HPV Genome Structure and Function 
Papillomavirus genomes consist of double-stranded circular DNA approximately 
8 kb in size, containing approximately 8 open reading frames (ORF) which are 
transcribed as polycistronic messages from a single DNA strand. The genome can be 
divided into three regions: an early region, a late region and long control region. The 
early region encodes six common open reading frames, E1, E2, E4, E5, E6 and E7. The 
E3 ORF does not encode a protein. The late region, positioned downstream of the early 
region, encodes the ORFs for the L1 and L2 capsid proteins. The long control region 
(LCR) or upstream regulatory region (URR) consists of 400-700 base pairs in length and 
holds the origin of replication and several transcription factor binding sites, but lacks any 
protein-coding function. However, the LCR does contain RNA regulatory signals in the 
late 3’UTR (3’-untranslated region). The proteins encoded from the early region are 
regulatory in function. Some of their functions include participation in HPV genome 
replication and transcription, cell cycle control, cell signaling and in the control of 
apoptosis. 
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The E1 protein functions as a viral initiator and is a DNA helicase/ATPase. The 
E2 protein is a DNA binding protein that regulates  viral gene expression  (Hegde, 2002). 
It can also inhibit the cell cycle, and when expressed at high levels can induce apoptosis 
(Desaintes, Demeret, Goyat, Yaniv, & Thierry, 1997). Together, these two proteins form 
an E1-E2 ori-complex that is necessary for the initiation of DNA replication and the 
maintenance of viral episomes in cells (Behren et al., 2005; Berg & Stenlund, 1997; 
Desaintes et al., 1997). Loss of E2 function due to disruption of the E2 ORF almost 
invariably accompanies viral DNA integration. This loss of E2 function leads to 
increased levels of the E6 and E7 oncoproteins that are necessary for creating and 
maintaining a transformed state in cells (Bosch et al., 1990). The E4 protein contributes 
to viral release by perturbing the cytokeratin network and increasing cellular fragility 
(Raj, Berguerand, Southern, Doorbar, & Beard, 2004). 
E5, E6 and E7 are considered the viral oncoproteins. Although less well-known 
than the E6 and E7 oncoproteins, E5 is considered an oncoprotein because of its ability to 
transform cells in culture and increase tumorigenicity in mice (Oelze, Kartenbeck, 
Crusius, & Alonso, 1995; Oh et al., 2009). Also, it has been found to be essential for the 
promotion and progression stages of carcinogenesis (Maufort, Genther Williams, Pitot, & 
Lambert, 2007). The oncoproteins  E6 and E7 from high-risk strains of the HPV virus are 
crucial for the induction and maintenance of the transformed phenotype in cells (Lembo 
et al., 2006; von Knebel Doeberitz, Bauknecht, Bartsch, & zur Hausen, 1991). Studies 
have established  that the E7 protein binds to, inactivates and accelerates the degradation 
of pRB and related proteins (Dyson, Howley, Munger, & Harlow, 1989). The HPV E7 
6 
protein also targets cell cycle and regulatory genes, resulting in the up-regulation of genes 
required for the G1/S transition and DNA synthesis. 
The HPV 16 E6 protein, which is the focus of this proposal, consists of 151 amino 
acids with two zinc fingers characterized by the CXXC motif (Barbosa, Lowy, & 
Schiller, 1989; S. Tungteakkhun & P. Duerksen-Hughes, 2008). The E6 oncoprotein has 
been shown to  stimulate the degradation of the p53 tumor suppressor protein by forming 
a ternary complex with the E6AP ubiquitin protein ligase and p53 (J. M. Huibregtse, 
Scheffner, & Howley, 1991; J M Huibregtse, Scheffner, & Howley, 1993; Scheffner, 
Werness, Huibregtse, Levine, & Howley, 1990; Werness, Levine, & Howley, 1990). 
However, E6 is multifunctional and has other activities that also contribute to 
malignancy. For example, it can modulate the transcription of cellular and viral 
promoters and the increase of cellular telomerase activity (Klingelhutz, Foster, & 
McDougall, 1996; Morjani et al., 2001). E6 also interacts with and accelerates the 
degradation of cellular proteins such as Bak and FADD, which are involved in apoptotic 
pathways (S. Tungteakkhun & P. Duerksen-Hughes, 2008). Our laboratory has shown 
that E6 can inhibit TNF-mediated apoptosis in cells by binding to the death domain of 
TNF-R1, preventing interaction with TRADD (M. Filippova, Song, Connolly, Dermody, 
& Duerksen-Hughes, 2002). We have also demonstrated that E6 binds to FADD, 
mediates its degradation, and thus prevents FAS-induced apoptosis (M. Filippova, 
Parkhurst, & Duerksen-Hughes, 2004). Cumulatively, these functions contribute to the 
oncogenicity of the E6 oncoprotein.  
In addition to the full-length E6 transcript, several truncated transcripts can be 
identified that result from differential splicing (David Pim, Paola Massimi, & Lawrence 
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Banks, 1997; Sherman & Schlegel, 1996). E6 is expressed as a full-length version (E6L) 
with several splice variants, including E6*I and E6*II. The splice variants E6*I and 
E6*II differ from each other by a few amino acids at the C-terminus, with E6*I being 
more abundant in cells. The truncated proteins are referred to collectively as E6*, while 
the full-length version is called E6 (full-length) (E6) (Tungteakkhun, Filippova, Fodor, & 
Duerksen-Hughes).  Research from our lab has generated strong evidence that these 
isoforms play separate and significant roles in cell signaling pathways (Maria Filippova 
et al., 2007; Tungteakkhun et al.). These findings support the idea that viruses can utilize 
differential splicing to expand the number of actions that they can perform.  
Our laboratory has contributed significantly to the current understanding of how 
HPV16 E6 modulates apoptosis. We have demonstrated that the full-length isoform is 
able to protect cells from apoptosis mediated by TNF, Fas and TRAIL (M. Filippova et 
al., 2002; Garnett, Filippova, & Duerksen-Hughes, 2006; Sandy S. Tungteakkhun, Maria 
Filippova, Jonathan W. Neidigh, Nadja Fodor, & Penelope J. Duerksen-Hughes, 2008). 
We have also demonstrated that the E6* splice isoform, which was previously thought to 
have no functional activity, is able to bind to and stabilize the procaspase 8 protein and 
thereby increase its expression (S. S. Tungteakkhun, M. Filippova, J. W. Neidigh, N. 
Fodor, & P. J. Duerksen-Hughes, 2008). 
 
The Viral Life-Cycle 
Infection with the human papillomavirus occurs at a site of wounding in the basal 
epithelial cells, and differentiation of the host cell is required for productive infection by 
the HPVs. As a consequence, the HPV life cycle is linked to the differentiation of the 
host’s epithelial cells. The HPV life cycle can be separated into two stages, a non-
8 
productive and a productive stage. In the non-productive stage, following entry into the 
basal epithelial cells, the HPV genome is established as an extrachromasomal 
autonomous element (episome). Approximately 50 copies of the episomal HPV genome 
are present at this stage, which allows for low level expression of some, but not all of the 
HPV genes. In order to establish a steady state level of viral genomes, the virus replicates 
its DNA in concert with division of basal and parabasal cells. 
As the life-cycle continues, subsets of daughter cells detach from the basement 
membrane and differentiate. It is here in the terminally differentiated layers of the 
epithelium that the productive stage occurs. The viral E6 and E7 proteins reactivate the 
cell’s DNA replication machinery and the virus amplifies its genome (Bedell et al., 1991; 
von Knebel Doeberitz et al., 1991). During this time, the E1 and E4 proteins are 
synthesized, along with the capsid proteins, and infectious virions are assembled. These 
virions are released into the environment as the epithelium’s upper layer is shed. 
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In low risk strains of the virus, replication begins in cells that are still 
proliferating.  However, in high risk strains, the replicative phase is confined to more 
differentiated cells that have already exited the cell cycle and are no longer carrying out 
DNA synthesis (John Doorbar et al., 1997).  
 
HPV Integration  
Although 95% of patients with precancerous lesions of the cervix harbor HPV, 
only a small fraction of these eventually progress to invasive carcinoma (Hopman et al., 
2006). Three premalignant stages, cervical intraepithelial neoplasia 1 (CIN1), cervical 
intraepithelial neoplasia 2 (CIN2), and cervical intraepithelial neoplasia 3 (CIN3) precede 
development of invasive carcinoma (invCA). CIN1 lesions typically regress 
spontaneously, with only a few lesions progressing to CIN2/CIN3 and eventually to 
invasive carcinoma (Snijders, Steenbergen, Heideman, & Meijer, 2006). It is therefore 
clear that although HR-HPV infection is a necessary event in cervical carcinogenesis, it is 
not sufficient for the pathogenesis of cervical cancer. Progression of cervical cancer in 
HPV infected women is tightly linked to integration status, and the frequency with which 
HR-HPV is found integrated in cervical cancers is consistently high.  For example, it has 
been reported that 100% of HPV18-, 80% of HPV16- and 81% of HPV31- positive 
cancers show viral integration (Cullen, Reid, Campion, & Lorincz, 1991; Pirami, Giache, 
& Becciolini, 1997).  
For these reasons, integration of the HR-HPV genome is usually considered a 
necessary event in the progression to cervical and other anogenital cancers, with an 
increase in the presence of integrated viral DNA correlating with disease progression 
(Arias-Pulido, Peyton, Joste, Vargas, & Wheeler, 2006; Briolat et al., 2007; Daniel, 
11 
Rangarajan, Mukherjee, Vallikad, & Krishna, 1997; Hudelist et al., 2004; Peter et al.; 
Schwarz et al., 1985; Vinokurova et al., 2008). Evidence indicates that the HPV genome 
is present in episomal form in early low-grade lesions (such as CIN1 and CIN2) while 
integration of the viral genome is observed in advanced stages of precancer and invasive 
carcinoma, suggesting that integration of HR-HPV genomes into the host genome occurs 
relatively late in the pathogenesis of cancer (Cullen et al., 1991; Wentzensen, 
Vinokurova, & Doeberitz, 2004). Furthermore, inflammation-mediated DNA damage 
frequently precedes the genomic abnormalities caused by HPV oncoproteins (Hiraku et 
al., 2007) thereby suggesting that HPV integration is involved in neoplastic progression.  
Integration  typically results in the increased expression and stability of transcripts 
encoding the viral oncogenes E6 and E7, which are known to inactivate and/or accelerate 
the degradation of numerous cellular proteins, including pRB (retinoblastoma protein) 
(E7) and p53 (tumor protein 53) (E6) (Hausen, 2000; S. Jeon & P. F. Lambert, 1995; 
Munger et al., 2004). The E2 ORF has been identified as the preferential site of 
integration because it is more commonly disrupted or deleted than any other site 
(Badaracco, Venuti, Sedati, & Marcante, 2002). The E2 protein negatively regulates E6 
and E7 expression, therefore, loss of this ORF during integration results in increased 
expression of the transforming E6 and E7 oncoproteins (Romanczuk & Howley, 1992). 
Thus, integration of the HPV genome results in the enhanced, deregulated expression of 
the viral oncogenes, E6 and E7, which are responsible for cellular transformation. In 
addition, it is thought that viral DNA integration disrupts critical cellular genes (Ferber et 
al., 2003) (Ferber et al., 0000; Popescu & DiPaolo, 1990). Both of these factors would 
contribute to neoplastic progression.  
12 
Relatively little is known of the process whereby HPV genomes become 
integrated into that of the host. However, several studies have suggested that DNA 
damage and agents that can induce DNA damage may play a role in HPV integration. A 
2007 study in W12 cells, which stably maintain HPV16 episomes, demonstrated that 
when double strand breaks (DSBs) are generated due to Ku70 depletion, new HPV16 
viral integration events occurred. Ku70 is a crucial mediator of DSB non-homologous 
end joining (NHEJ). This data indicates that DSBs may be associated with HPV 16 
episome loss and integration in cervical cancer (D. Winder et al., 2007). In the case of 
another DNA virus, Hepatitis B, that causes hepatocellular cancer and in which viral 
DNA integration coincides with severe dysplasia, studies have shown that integration 
frequency increases with DNA damage (M. Dandri et al., 2002). Therefore, it is 
reasonable to expect that the integration of viral DNA into that of the host would be 
enhanced by damage to both the viral episome and the host DNA, as this would create a 
site for integration.  
Inflammation mediated DNA damage therefore provides a potential mechanism 
by which HPV integration could occur in the progression of cervical cancer.  Indeed, 
inflammation has been implicated in the progression of a variety of cancers, and it has 
been suggested that the excessive amounts of reactive oxygen and nitrogen species 
produced during chronic inflammation play a role in carcinogenesis by promoting DNA 
damage (Kawanishi, Hiraku, Pinlaor, & Ma, 2006). In the case of HPV-associated 
cancers, inflammation would also facilitate the integration of the viral genome by 
inducing breaks in both the viral and host genomes.  
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Cofactors for HPV Oncogenesis 
Several co-factors, in addition to HPV infection, have been associated with the 
progression to cancer. Smoking, long term use of oral contraceptives and parity have all 
been suggested to serve as co-factors for the development of cervical cancer (Almonte et 
al., 2008). Among these cofactors, the case for smoking as a cofactor is perhaps the 
strongest, as evidence shows that it precedes the development of cervical pre-cancer and 
cancer, and increases the risk of developing cervical cancer in HPV positive women 
(Deacon et al., 2000; Plummer et al., 2003). Smoking leads to DNA-adduct formation 
and thus DNA damage, a possible mechanism for cancer development. High parity may 
also be mechanistically linked, as it causes cervical trauma and cellular oxidative and 
nitrosative stress, all of which can lead to DNA damage and contribute to cancer 
progression. Women with seven or more full-term pregnancies (FTPs) are at higher risk 
of developing cervical cancer than those with only one or two, indicating that as the 
number of FTPs increase so does the risk of developing cervical cancer (Almonte et al., 
2008). Women also increase their risk of cervical cancer through the long term use of oral 
contraceptives (La Vecchia & Boccia, 2014).  
Another co-factor involved in the development of cervical cancer is co-infection 
with other sexually transmitted diseases (STDs), either viral or bacterial in nature. Such 
infections can cause inflammation, and in HPV-infected women, cervical inflammation is 
associated with cervical neoplasia (Castle & Giuliano, 2003; Castle et al., 2001). It is 
important to note that this inflammation is not typically due to HPV itself, in part because 
the immune system is largely ineffective against the human papillomavirus. HPV infects 
keratinocytes, which are distant from immune centers and have a naturally short lifespan. 
In addition, the virus does not need to destroy the cell, and so inflammation is not 
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typically triggered (Stanley, 2006). Despite this, high levels of inflammatory mediators 
are observed in cervical cancer. For example, COX-2, an enzyme responsible for 
prostaglandin formation, is over-expressed in cervical cancer (Kim et al., 2004; Kulkarni 
et al., 2001). COX are a family of enzymes that catalyze the formation of prostaglandins 
from arachidonic acid (Saldivar et al., 2007). The COX-2 isoform is induced in response 
to inflammatory factors and is expressed in early stage premalignant lesions, including 
cervical tissues (Saldivar et al., 2007). One study found that 100% of the cervical cancer 
samples tested showed COX-2 expression, compared with only 7.7% in normal samples 
(Hammes et al., 2008). Also, Nuclear factor-κ[kappa]B (NFκB), a master transcription 
factor that is essential for promoting inflammation associated carcinogenesis (Pikarsky et 
al., 2004; Ravi & Bedi, 2004), is over-expressed in cervical lesions co-expressing 
Chlamydia T. and HPV.  
Since HPV infection of the cervix by itself is not inflammatory, viral (such as 
Herpes Simplex Virus, HSV) and bacterial (such as Chlamydia Trachomatis, CT) 
infections serve as the main sources of cervical inflammation. Chlamydia Trachomatis is 
a well-known cause of the inflammatory condition, cervitis, and cervical cancer cells 
infected with Chlamydia Trachomatis secrete higher levels of proinflammatory cytokines 
than uninfected cervical cancer cells (Rasmussen et al., 1997). Several recent studies 
have determined that co-infection with either CT or HSV is associated with a greater risk 
of developing cervical cancer (Finan, Musharrafieh, & Almawi, 2006), and have also 
pointed to an association between the development of cervical cancer and other sexually 
transmitted infections such as Neisseria gonorrhoeae (Hawes & Kiviat, 2002).  In 
addition, co-infection of HPV 16 with herpesviruses such as CMV and EBV, as well as 
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with HSV2, increased the frequency of HPV-16 integration (Szostek, Zawilinska, Kopec, 
& Kosz-Vnenchak, 2009), and Chlamydia Trachomatis infection was shown to favor the 
entry and persistence of multiple HR-HPV types in cervical epithelium (Paba et al., 
2008). A paper by Schwebke and Zajackowski reported that it was the inflammation 
caused by such infections, rather than the particular infection itself, that was associated 
with squamous intraepithelial lesions within the cervix (Hawes & Kiviat, 2002). Infection 
induced inflammation has also been shown to increase the risk of other HPV-induced 
cancers, such as penile cancer, where infection with genital lichen sclerosis increases the 
risk of neoplasia in HPV infected men (Barbagli et al., 2006; Nasca, Innocenzi, & Micali, 
2006). The inflammation produced as a result of such co-infections can induce the 
generation of ROS, which can in turn contribute to the initiation and progression of 
cancers through damage to DNA. Thus, factors that affect the generation of reactive 
oxygen species, such as smoking and inflammation, may cause DNA damage and affect 
HPV integration. As such, they may share a common mechanism in inducing severe 
neoplasia. 
 
Reactive Oxygen Species (ROS) in Cells 
Reactive oxygen species (ROS) and antioxidants exist in a delicate balance in 
cells. Oxidative stress occurs when this balance is disrupted due to either an increase in 
the ROS levels in cells, a decrease in the antioxidant levels, or both (Sies, 1997b). Free 
radicals play a well-known role in the initiation and promotion of carcinogenesis. They 
are molecules that contain one or more unpaired electrons, which allow them to be very 
reactive. They are capable of activating pro-carcinogens, altering the level of cellular 
antioxidant enzymes, and causing damage to DNA and other biomolecules (Sun, 1990). 
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In turn, antioxidants scavenge the free radicals that cause damage to DNA and other 
molecules, and in cases where free radicals are increased over normal levels, cells can 
respond by increasing antioxidant synthesis (Valko, Rhodes, Moncol, Izakovic, & Mazur, 
2006b). Endogenous ROS originates from the mitochondria, cytochrome P450 
metabolism, peroxisomes, and inflammatory cell activation (Inoue et al., 2003). Among 
these, the mitochondria are the primary source of the free radicals hydrogen peroxide and 
superoxide in cells. Since mitochondrial oxidative phosphorylation is the major source of 
free radical generation, mitochondria are enriched with antioxidant enzymes such as 
superoxide dismutase (SOD) and glutathione peroxidase (Gpx) (Cadenas & Davies, 
2000; F. M. Yakes & VanHouten, 1997). During the process of oxidative 
phosphorylation, oxygen is reduced to water in a four-step addition of electrons (Breen & 
Murphy, 1995), and in some cases, intermediates escape (see Figure 3). These can 
include the superoxide radical, which is then converted to the hydrogen peroxide radical 
by superoxide dismutase. The hydrogen peroxide is reduced to water and molecular 
oxygen by glutathione peroxidase. Hydrogen peroxide can also be converted via the 
Fenton reaction to the highly reactive and dangerous hydroxyl radical (Breen & Murphy, 
1995).  
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High levels of oxidative stress have been demonstrated the ability to  induce 
damage to DNA (Kawanishi, Hiraku, & Oikawa, 2001). The highly reactive hydroxyl 
radical interacts with DNA, damaging both purine and pyrimidine bases (Dizdaroglu, 
Jaruga, Birincioglu, & Rodriguez, 2002). The reaction of the hydroxyl ion with guanine, 
the most easily oxidized base, leads to formation of the most common base modification, 
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) (Kawanishi et al., 2001; Steenken & 
Jovanovic, 1997). ROS-induced DNA damage results in single and double strand breaks, 
abasic sites, modified bases and DNA cross-linking (Demple & Harrison, 1994; Marnett, 
2000). This damage to DNA leads to mutagenesis and in some cases, to cancer. 
In cancer, the antioxidant capacity of cells is frequently diminished. Tumor cells 
have been shown to be generally low in manganese superoxide dismutase activity, 
usually low in copper and zinc superoxide dismutase activity, and almost always low in 
catalase activity (Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006a). The activity of 
glutathione peroxidase and glutathione reductase is highly variable in these cells (Sun, 
1990). It is possible that these factors contribute to the high levels of oxidative stress 
normally observed in tumor cells. 
 
Oxidative Stress in Viral Infections 
The occurrence of oxidative stress during a viral infection is an established 
phenomenon and has been demonstrated in several viral infections including human 
immunodeficiency virus (HIV), hepatitis B virus (HBV) and influenza (K. B. Schwarz, 
1996). As a result, there is increased interest in understanding the role of oxidative stress 
in the pathogenesis of viral infection. Viral infection is known to induce overproduction 
of reactive oxygen species (ROS), nitric oxide, superoxide and their reaction product, 
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peroxynititrite, all of which contribute to oxidative stress (Akaike et al., 1990). Apart 
from the increased generation of reactive oxygen species in cells, viral infection can also 
increase oxidative stress by decreasing the antioxidant levels in these cells. In mice 
infected with influenza A, for example, there is a decrease in the total glutathione and 
Vitamin C levels, which in turn causes increased oxidative stress in the cells (Hennet, 
Peterhans, & Stocker, 1992). Work done by van Pelt et al has demonstrated that HBV 
replication can modulate host gene expression and induce oxidative stress in infected 
cells (Severi et al., 2006). Research by Hagen et al demonstrated that mice infected with 
hepatitis B demonstrated an increase in oxidative DNA damage in the preneoplastic foci 
of the liver (Hagen et al., 1994). Zhang et al demonstrated that in hepatitis B infection, 
oxidative DNA damage was caused by an increase in oxidative stress, thus increasing the 
frequency of viral integration (Petersen, Dandri, Burkle, Zhang, & Rogler, 1997). In host 
cells for hepadnavirus, it has also been shown that viral DNA integration can be 
mutagenic, increasing the risk of cancer in their host (Popper, Shafritz, & Hoofnagle, 
1987).  Consequently, it has been suggested that viral genes may induce oxidative stress 
leading to DNA damage (Maura Dandri et al., 2002). 
One method that can be used by the cell to counteract the oxidative stress 
resulting from viral infection is to increase expression of the cell’s antioxidant enzymes. 
The three main classes of antioxidant enzymes are superoxide dismutase, catalase and 
glutathione (GSH) peroxidase (Sies, 1997b).  In the case of human influenza A virus 
infection, increased mRNA expression of the antioxidants Mn-superoxide dismutase 
(SOD2) and indoleamine 2,3-dioxygenase was observed (Kathleen B. Schwarz, 1996).  
Roederer et al showed that while HIV infection is associated with decreased levels of 
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glutathione and cysteine, there is an increase in catalase levels, which may partially 
compensate for the decreased levels of the other two antioxidants (M. Roederer, Ela, 
Staal, Herzenberg, & Herzenberg, 1992; Mario Roederer, Staal, Osada, Herzenberg, & 
Herzenberg, 1991). Since oxidative stress is caused by an imbalance of cellular oxidants 
and antioxidants, it is possible that its effect can be alleviated by the administration of 
exogenous antioxidants. Antioxidants are known to inhibit viral replication and reduce 
virus induced oxidant injury. In fact, N-acetylcysteine, an antioxidant, has been shown to 
inhibit HIV replication and apoptosis in vitro (Newman, Balcewicz-Sablinska, 
Guarnaccia, Remold, & Silberstein, 1994). Antioxidants can also decrease the long-term 
effects of chronic oxidative stress, a occurrence that has been linked to the progression to 
cancer (Peterhans, 1997). 
 
Model for Inflammation Induced HPV Integration in Cells 
Based on the evidence presented, we propose a scheme for the involvement of 
inflammation in HPV carcinogenesis in Figure 4. Approximately 80% of women will be 
exposed to HPV within their lifetime. In the majority of these cases, the infection will 
spontaneously clear.  On occasion, CIN1 lesions will develop, but most of these lesions 
will also spontaneously clear. However, in some cases, HPV infected women will 
develop cervical inflammation caused by co-infection with either a viral or bacterial 
agent. Alternatively, inflammation could be caused by other co-factors such as smoking. 
This inflammation will facilitate the progression of CIN1 lesions to CIN2 due to the cell 
proliferative effects of inflammation combined with the low level expression of the E6 
and E7 viral oncogenes from episomal HPV. At the CIN2 stage, the inflammation-
induced generation of reactive oxygen and nitrogen species induces DSBs in both the 
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viral and host DNA. This allows HPV integration to occur. HPV integration then leads to 
disregulated expression of the viral oncogenes E6 and E7, (CIN3) and eventually to 
invasive carcinoma (invCA). 
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Purpose of This Study 
As mentioned previously, HPV infection alone is known not to be a sufficient 
cause for the development of disease; other cofactors are necessary. One such cofactor is 
likely to be oxidative stress. This is of particular interest to us since oxidative stress can 
cause DNA damage. In almost all cases of cervical cancer, the HPV genome is found 
incorporated into the host genome, indicating that this is usually a necessary event for the 
development of cancer. Oxidative stress in cells would allow for the necessary DNA 
damage that facilitates incorporation. 
The HPV life cycle and its role in carcinogenesis have been intensively studied 
over the last three decades. However, little is known about why high risk strains of HPV 
sometimes become incorporated into the host genome or which HPV genes, if any, are 
involved in the process of integration. Therefore, to begin to explore these phenomena we 
asked the following questions: 1) Does E6 expression affect the level of cellular oxidative 
stress in cells, and if so, what is/are the molecular mechanism(s)? 2) Does expression of 
either of the E6 isoforms affect the level of DNA damage in cells? The results from this 
study will allow us to begin to elucidate the process of high-risk HR-HPV integration, a 
critical step in cell transformation. 
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Abstract 
High risk types of Human Papillomavirus (HPV) are the causative agents of 
virtually all cases of cervical cancer and a significant proportion of other anogenital 
cancers, as well as both oral and pharyngeal cancers. The high-risk types encode two 
viral oncogenes, E6 and E7, which work together to initiate cell transformation. Multiple 
steps, involving the activities and interactions of both viral and cellular proteins, are 
involved in the progression from HPV infection to cell transformation to cancer. The E6 
oncoprotein is expressed as several isoforms, a full-length variant referred to as E6 and a 
few shorter isoforms collectively referred to as E6*. In this study, we found that 
expression of E6* increased the level of reactive oxygen species (ROS) in both HPV+ 
and HPV- cells. This increased oxidative stress led to higher levels of DNA damage, as 
assessed by the comet assay, quantification of 8-oxo-G, and PARP expression. The 
observed increase in ROS may be due to a decrease in cellular anti-oxidant activity, as we 
found that E6* expression also led to decreased expression of SOD2 and Gpx. These 
studies indicate that E6* may play an important role in virus-induced mutagenesis by 
increasing oxidative stress and DNA damage. 
26 
Introduction 
High risk types of Human Papillomavirus (HR HPV) are the causative agents of 
virtually all cases of cervical cancer as well as a significant percentage of other 
anogenital and oropharyngeal cancers. In fact, current estimates indicate that HPV 
infection may be associated with as many as 93% of anal cancers, 63% of oropharyngeal 
cancers, 40% of penile cancers, 64% of vaginal cancers and 51% of vulvar cancers 
(Parkin & Bray, 2006). HPV infection accounted for approximately 26,700 cases of 
HPV-related cancers in the US (Gargano et al., 2012; Steinau et al., 2013), and it is 
estimated that 5.2% of all cancers worldwide can be attributed to HPV infection (Parkin, 
2006). While the incidence of cervical cancer has declined in the last 30 years due to PAP 
smear screening, the incidence rates of anal, oropharyngeal and vulvar cancers has 
steadily increased within that same period (Parkin & Bray, 2006). These numbers 
underscore the need for ongoing research into the mechanisms behind HPV-related 
carcinogenesis. 
The high-risk types of HPV encode two viral oncogenes, E6 and E7, that together 
serve as the major initiators of cell transformation (Munger et al., 2004). Multiple steps 
are involved in the progression from HPV infection to cellular transformation to cancer. 
Virus-related factors influencing this progression include virus persistence, viral load, 
and the re-programming of target cell function by HPV early genes to favor virus 
production. In rare cases, infection plus subsequent events can lead to HPV genome 
integration. The significance of viral genome integration in HPV mediated carcinogenesis 
is illustrated by the fact that most cases of HPV-mediated cervical cancer present with the 
genome in an integrated form (zur Hausen, 2002). Frequently, this integration allows for 
the unregulated expression of the viral oncogenes E6 and E7 (Munger et al., 2004).  
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In addition to these virus-related factors, genetic susceptibility to viral infection, 
increasing age of the host, and other epigenetic and lifestyle factors such as smoking, 
chronic inflammation and co-infection with other STDs, particularly Chlamydia 
trachomatis, have been shown to increase the risk of progression to cervical cancer in 
HPV infected women (Gravitt Pe, 2001). Several of these factors can be logically linked 
to increased oxidative stress and DNA damage. Extensive DNA damage usually leads to 
apoptosis (Kaina, 2003), but in cells infected with HPV, the viral oncogenes E6 and E7 
rescue cells from this pathway, resulting in mutagenesis, increased cell proliferation and 
in rare instances, cancer (C. A. Moody & L. A. Laimins, 2010). One of the factors shown 
to promote cellular transformation is oxidative stress. Oxidative stress during viral 
infection can be a result of the immune response to viral proteins and/or a consequence of 
viral gene expression. Oxidative stress causes oxidative DNA damage which may 
facilitate HPV-DNA integration (Williams, Filippova, Soto, & Duerksen-Hughes, 2011). 
A link between virus induced oxidative stress and viral pathogenesis has been 
demonstrated in several viral infections, including Epstein Barr Virus (EBV), Hepatitis C 
virus (HCV) and Hepatitis B virus (HBV). For example, in the case of HBV associated 
hepatocellular cancer, it has been shown that the accumulation of HBV mutant surface 
proteins in the endoplasmic reticulum of infected cells induces oxidative DNA damage in 
the late stages of infection. In HCV induced hepatocarcinogenesis, chronic infection with 
HCV is characterized by increased oxidative stress. In the case of EBV and 
nasopharyngeal cancer, the lytic life cycle and the viral oncogene EBNA-1 have both 
been shown to induce oxidative stress (Hsieh et al., 2004; Kamranvar & Masucci, 2011; 
Ma et al., 2008; Taylor, Raghuwanshi, Rowe, Wadowsky, & Rosendorff, 2011; Tsai & 
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Chung, 2010). In these cases, an increase in oxidative stress both causes direct oxidative 
DNA damage, and also participates in various signaling pathways that can lead to 
chromosomal aberrations and cell transformation. 
In the case of HPV infection, the host immune response is generally limited and 
viral infection itself does not induce a state of chronic inflammation.  The primary reason 
for this is that the virus infects basal epithelial cells, which are shielded from circulating 
immune cells during the initial stages of infection. Nevertheless, reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) have potential significance to the 
development of viral carcinogenesis.  For example, one study showed that exposing cells 
infected with HPV 16 to the reactive nitrogen species nitric oxide increased the levels of 
E6 and E7 and increased the level of DNA damage (Wei, Gravitt, Song, Maldonado, & 
Ozbun, 2009). Also, previous research has shown that the expression of HPV 16 E6 in 
L929 cells increases ROS accumulation (Liu, Tergaonkar, Krishna, & Androphy, 1999).  
HPV16 E6 is expressed in cells as two main isoforms, a full-length variant (E6) 
and a few similarly truncated variants frequently referred to collectively as E6* due to 
their similarity. The function and activities of the full-length oncoprotein, E6, have been 
intensively studied over the last two decades (Howie, Katzenellenbogen, & Galloway, 
2009; C. A. Moody & L. A. Laimins, 2010; S. S. Tungteakkhun & P. J. Duerksen-
Hughes, 2008). In contrast, relatively little is known regarding the activities of the 
truncated E6* isoform, and its significance in both the viral life cycle and in 
carcinogenesis has been disputed. The early transcripts produced from the early promoter 
located upstream of the E6 gene can undergo alternative splicing from a donor site 
located within the E6 gene (nucleotide (nt) 226 in the case of HPV16) to an acceptor site 
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that can be located either within or outside of the E6 gene. This results in the production 
of several E6* splice variants. This splicing pattern is a unique characteristic of all high-
risk HPV types, and is not restricted to HPV 16 and HPV 18. Rather, it is also present in 
the high-risk types HPV 31, HPV 33, and HPV 45, which together with HPV 16 and 18 
are responsible for almost all cases of cervical cancer. Interestingly, E6* is the most 
abundant splice variant produced during the early stages of infection (Heer, Alonso, & de 
Prat-Gay, 2011). In contrast, low-risk types do not express E6* due to the absence of the 
consensus splice site. Work done in both our laboratory and that of Dr. Banks suggests 
significant and independent roles for the E6* splice variant.  For instance, we observed 
that over-expression of E6* in SiHa cells sensitized these cells to both TNF- and Fas-
induced apoptosis (Maria Filippova et al., 2009b), and that full-length E6 and E6* bind to 
different regions on procaspase 8 and have opposite effects on the stability of that protein 
(Tungteakkhun, Filippova, Fodor, & Duerksen-Hughes, 2010). Work done by the Banks 
group has shown that HPV18 E6* regulates the ability of the full-length isoform to 
degrade p53, with an inverse relationship between the level of E6* and the ability of full-
length E6 to degrade p53 (Pim & Banks, 1999). This group has also shown that E6* can 
suppress the growth of transformed cells (D. Pim, P. Massimi, & L. Banks, 1997). Taken 
together, these observations suggest that E6* possesses important and distinct functions 
from the full-length isoform of E6.  
In the current study, we discovered that E6*, but not E6, increases cellular ROS 
and leads to higher levels of DNA damage. Modulation of the ratio of E6 isoforms can 
change these ROS levels, with increased proportions of E6* consistently promoting 
oxidative stress. We also investigated the mechanisms responsible for these changes, and 
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found that the truncated versions of E6 may modulate the expression of enzymes 
involved in ROS metabolism, thereby leading to higher levels of ROS and DNA damage. 
 
Materials and Methods 
Reagents 
 
Monoclonal α-SOD1 and α-Glutathione peroxidase were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Monoclonal  -SOD2 was obtained from BD 
Biosciences (Franklin Lakes, NJ), and monoclonal α-PARP 1 was purchased from 
Calbiochem (Billerica, MA). Monoclonal  -β-actin was obtained from Sigma-Aldrich (St. 
Louis, MO). Monoclonal antibodies directed against the HPV16 E6 N-terminus were 
obtained from Euromedex (France).  MG132 was purchased from Sigma-Aldrich (St. 
Louis, MO). 
Cell Culture 
 
CaSki and SiHa cells (derived from human cervical carcinomas), L929 (mouse 
fibrosarcoma) and U2OS (human osteosarcoma) cells were obtained from the ATCC 
(Manassas, VA). CaSki, SiHa cells and L929 cells were cultured in modified Eagle 
medium (MEM) (CellGro, Manassas, VA), U2OS was cultured in McCoy’s 5a Medium 
Modified, and normal oral keratinocyte (NOK) cells were grown in Keratinocyte Serum 
Free Medium (Invitrogen, Carlsbad, CA). The medium for all cells was supplemented 
with penicillin (100 u/ml) and streptomycin (100 µg/ml) (Sigma-Aldrich, St. Louis, MO). 
MEM and McCoy 5a were supplemented with 10% FBS (Invitrogen, Carlsbad, CA).  
 
 
Plasmids, siRNA Inhibition and Transfections 
Plasmids pFlag-E6 and pFlag-E6* were obtained by cloning E6  and E6* in frame 
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with the N-terminal Flag-tag and the C-terminal C-myc-tag into the pFlag-myc CMV-22 
vector (Sigma-Aldrich, St. Louis, MO). Cloning of Flag-E6* and Flag-E6 into the 
retroviral vector pLNCX (BD Clontech, Mountain View, CA) and production of 
retroviral stocks have been described previously (Filippova et al 2009). To inhibit the 
expression of E6, target sequences for shE6, as well as the scrambled sequence, were 
cloned into pSilencer 3.1 (Invitrogen, Carlsbad, CA) (Filippova et al, 2009). 
Transfections were carried out using the TransIT®-2020 Reagent (Mirus Bio, 
Madison, WI), as directed by the manufacturer. For transient transfections, cells were 
analyzed 48 h post-transfection. SiHa- and CaSki-derived stable cell lines were obtained 
by transfection of the parental cells with the corresponding plasmids, followed by G418 
or puromycin selection for 2 to 3 weeks. NOK-derived stable cell lines were produced by 
transduction of retrovirus pLNCX, pLNCX-E6* or pLNCX-E6, followed by isolation of 
clones derived from single cells. Individual clones were selected, grown and analyzed for 
protein expression by immunoblotting and/or RT-PCR. 
Expression of SOD2 in NOK cells was decreased by siRNA inhibition, employing 
the siControl and siSOD2 oligos obtained from Invitrogen (Grand Island, New York). X-
tremeGENE siRNA transfection reagent (Roche Diagnostics, Mannheim Germany) was 
used to transfect these cells with the siControl and siSOD2 siRNA oligos according to the 
manufacturer’s protocol.  
 
Measurement of ROS by Flow Cytometry 
 
Cellular levels of hydrogen peroxide, hydroxyl and peroxyl radicals (H2O2, OH- 
and ROO-) and superoxide (O2−) were estimated using 5-(and-6)-Carboxy-2',7'-
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Dichlorodihydrofluorescein Diacetate (DCF) or Dihydroethidium (DHE), respectively 
(Peshavariya, Dusting, & Selemidis, 2007). All fluorescent probes were purchased from 
Invitrogen (Carlsbad, CA). 20 mM stock solutions were diluted into culture media, and 
added to cells to a final concentration of 10 µM DCF and 5 µM DHE. Cells were 
incubated at 37ºC in the dark for 25-30 minutes. After treatment, cells were trypsinized, 
washed and collected in PBS. Cells were analyzed using the Becton-Dickinson 
FACSCalibur flow cytometer (BD, Franklin Lakes, NJ). A total of 10,000 events were 
measured per sample. DCF was detected in the FL-1 channel (530/30 nm), while DHE 
was detected in the FL-2 channel (650 nm). Data was collected in log scale and analyzed 
using Cell Quest Pro and Flow-Jo software.  
 
Immunoblotting and Immunoprecipitation 
For immunoblot analysis, 106 of the indicated cells were lysed in 200 µl Laemmli 
Lysis Buffer, and lysates were separated by SDS-PAGE. After transfer of protein onto 
Immobilon P membranes (Millipore, Billerica, MA) and blocking of the membrane with 
1% BSA, primary antibodies, diluted in Tris-buffered saline-Tween-20 (TBST) were 
applied. After incubation at 40C overnight, membranes were washed with TBST and 
secondary ImmunoPure antibody ( -mouse or  -rabbit) conjugated with HRP (Thermo 
Scientific) was applied. Signal was detected using the chemiluminescent SuperSignal 
West Femto or Pico maximum-sensitivity substrate (Thermo Scientific, Rockford, IL). 
For detection of the E6 isoforms in SiHa pSilencer, SiHa siE6, SiHa pFlag and SiHa 
pE6* cells, 106 cells were pretreated with 10 μM MG132 16 h prior to preparation of the 
lysates. The cells were collected and lysed in 100 μl of RIPA buffer (Sigma-Aldrich). 
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For immunoprecipitation, 107 cells from each of the NOK clones, NOK pLNCX 
and NOK pLNCX-E6, were treated with 10 μM MG132 for 16 h prior to preparation of 
lysates. Flag-tagged proteins were then precipitated using Flag-agarose, and bound 
proteins were subjected to SDS-PAGE, then transferred to a PVDF membrane and 
detected by immunoblot. Detection of Flag-E6* and Flag-E6 were performed using α-
Flag-HRP antibodies. 
 
Comet Assay 
The comet assay was performed using the Trevigen Kit (Trevigen, Gaithersburg, 
MD) under alkaline conditions. Nuclei were stained with SYBR® GOLD (Invitrogen, 
Carlsbad, CA). For each sample tested, 100 DNA tails were photographed and analyzed. 
The length of each tail was measured from the center of the comet to the end of the tail 
using Image J software, and each tail was categorized into one of four tail types reflecting 
the severity of DNA damage. DNA damage was classified into four classes of tail lengths 
(0-50, undamaged; 50-100, minimum damage; 100-150, medium damage; >150, 
maximum damage) such that the severity of DNA damage increases proportionately with 
tail length.  
 
8-Oxyguanine DNA Damage Analysis 
DNA damage was determined by binding the FITC conjugate to 8-oxo-
deoxyguanosine (8-oxodG). Cells were fixed in 1% paraformaldehyde and permeabilized 
in methanol. After fixation and permeabilization, cells were washed, blocked, and 
incubated with OxyDNA FITC conjugate (Calbiochem, San Diego, CA) for 1 hour in the 
dark. Cells were resuspended in PBS and analyzed by flow cytometry for fluorescence  
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(excitation 495 nm, emission 515 nm) on the BD FACS Calibur (BD, Franklin Lakes, 
NJ). Data was analyzed using the Flow-Jo software. A total of 10,000 events were 
measured per sample. 
 
RNA Isolation and RT-PCR 
Cells were plated in a 10 cm tissue culture plate and allowed to grow to 80 
percent confluency. RNA was isolated using Tri Reagent according to the manufacturer’s 
protocol (Sigma Aldrich, St. Louis, MO). cDNA was synthesized using ImPromII reverse 
transcriptase (Promega, Madison, WI) and an oligo(dT) primer. Primers for the 5’ and 3’ 
ends of Flag (5’ ATGGGCGGTAGGCGTGTAC 3’ and 5’ GGTCACAGGGATGCCAC 
3’) were used to amplify PCR products for the E6 full length and splice variants 
expressed from plasmids.  Primers for the 5’ and 3’ ends of E6 (5’ 
AATGTTTCAGGACCCACAGG 3’ and 5’ CACACAACGGTTTGTTGTATTGCTG 
3’) were used to amplify PCR products for the E6 full length. The E6* splice variant was 
amplified using the same primer for the 5’ end with a different primer for the 3’ end (5’ 
CTTTTGACAGTTAATACACCTCACG 3’) (Hafner et al., 2008). The PCR product 
from PGK1, using primers 5’ CTGTGGGGGTATTTGAATGG 3’ and 5’ 
CTCCAGGAGCTCCAAACTG 3’ was used for normalization. 
 
qRT-PCR 
Quantitative real-time PCR (qRT-PCR) to measure the levels of the E6 isoforms 
was conducted using primers designed as described previously by Hafner et al. (Hafner et 
al., 2008) along with the Absolute QPCR Sybr green kit according to the manufacturer’s 
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protocol (Bio-Rad Laboratories, Inc.). Observed E6 isoform concentrations were 
normalized using the level of β-actin or 36B4 expression.  
 
Statistics 
All assays were repeated at least three times. Results are reported as mean ± s.d. 
Differences were analyzed by Student’s t-test. P<0.05 was regarded as significant. 
 
Results 
ROS Levels are Higher in CaSki than in SiHa Cells 
Our initial studies examining the influence of E6 and E6* on ROS levels were 
done using CaSki and SiHa cells, which are well-known cellular models of cervical 
cancer derived from HPV 16+ cervical carcinomas. ROS levels in SiHa and CaSki cells 
were estimated using flow cytometry following staining with the fluorescent dyes 5-(and-
6)-carboxy-2',7'-dichlorofluorescein diacetate (DCF) (detects hydrogen peroxide, 
hydroxyl and peroxyl redicals) and dihydroethidium (DHE) (Peshavariya et al., 2007) 
(detects superoxide radicals). The flow cytometry results clearly demonstrated that the 
levels of both species were higher in CaSki cells than in SiHa cells (Figure 1A).These 
results were repeated three times to generate the bar graphs shown in Figures 1B and 1C. 
Because previous studies suggested that E6 may be responsible for the increase in ROS 
(Liu et al., 1999), we postulated that the difference in ROS levels between these cell lines 
might be due to differences in E6 expression. Interestingly, the level of expression of full 
length E6 was similar in both cell lines, while the level of expression of E6*I (M. 
Filippova et al., 2014), the most abundant splice product (referred to as E6* from this 
point forward) was much higher in CaSki than in SiHa cells (Figure 1D and 1E). These 
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findings are consistent with results we obtained earlier concerning the ratio between E6 
and E6* protein levels (Maria Filippova et al., 2009a). Since both the ratio of E6*/E6 
expression and the absolute level of E6* expression differ between these cell lines, it was 
possible that either or both factors could contribute to the elevated ROS levels.  
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Increased E6*/E6 Ratios Cause Higher Levels of ROS in SiHa Cells 
If a difference in the ratio between E6 isoforms was the major factor determining 
the difference in ROS levels, one resulting prediction is that changing the ratio between 
E6 and E6* should alter the level of ROS. To test this idea, we decreased E6 expression 
in SiHa cells such that the ratio of E6*/E6 would increase. We designed shRNA to target 
E6 and cloned it into the pSilencer vector, then stably transfected either the empty vector 
or pshE6 into SiHa cells to generate the SiHa pSilencer control cell line and the stable 
cell line SiHa shE6, respectively . qRT-PCR analysis (Figure 2A) and immunoblot data 
(Figure 2B) both showed that E6 expression was indeed decreased in these cells. Figure 
2C shows the bar graph generated following staining of these SiHa-derived cells with 
DCF, demonstrating that increasing the relative ratio of E6*/E6 expression in SiHa cells 
led to a parallel increase in the level of ROS as compared to the control cell line SiHa 
pSilencer.  
To further evaluate the possibility that differences in the E6*/E6 ratio may affect 
ROS levels, we also manipulated the ratio of E6 isoform expression by increasing the 
relative amount of E6* in SiHa cells. E6* was cloned into the pFlag vector in frame with 
the Flag tag at the N-terminus and C-myc at the C-terminus, and stable cell lines 
expressing the vector-derived E6* were produced. To eliminate the effect of clonal 
integration, six clones with the highest level of E6* expression were combined to produce 
SiHa pE6* pooled cells. These cells, together with SiHa pFlag control cells, were stained 
with DCF and analyzed by flow cytometry. DCF staining was carried out in triplicate to 
produce the bar graph shown in Figure 2F. The results clearly demonstrate that the SiHa 
pE6* pooled cell line displayed higher levels of ROS than did control cells transfected 
with the empty vector. Thus, over-expression of the E6* isoform in SiHa cells was able 
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to further increase ROS levels in these cells. qRT-PCR analysis and immunoblot data 
(Figures 2D and 2E respectively) confirmed the higher level of E6* expression in SiHa 
pE6* cells as compared to vector control cells.   
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Over-expression of E6*, But Not of Full Length E6, Increases ROS 
Levels in Cells 
The experiments described above demonstrate that manipulating E6 isoform 
levels so that the E6*/E6 ratio increased also increased ROS levels. However, in these 
experiments, both isoforms were present, potentially complicating interpretation. To 
address this limitation, we individually expressed E6 and E6* in the HPV-, non-cervical 
cancer cell lines U2OS (human osteosarcoma) and L929 (mouse fibrosarcoma). Cells 
were transiently transfected with the pFlag plasmid coding for E6, E6* or the empty 
vector (control). Forty-eight hours post-transfection, these cells were stained with DCF 
for ROS analysis using the fluorimetric plate reader. In both U2OS- and L929- derived 
cell lines, ROS levels were increased in cells expressing pE6* as compared to those 
expressing the vector control or pE6 (Figure 3A and 3C respectively). Figures 3B and 3D 
show RT-PCR data confirming the expression of E6L and E6* in U2OS and L929 cells 
respectively. These findings indicate that the actual level of E6* expression is responsible 
for the increase of ROS levels in cells, and also that the effect of E6* on ROS levels is 
independent of the presence or absence of other HPV proteins.  
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ROS Levels are Higher in NOK Cells Expressing E6* 
The findings discussed above were demonstrated in transformed cancer cells. To 
ask whether the activities of full-length E6 and/or E6* might contribute to differences in 
cellular ROS in non-transformed target cells, the influence of each isoform on ROS levels 
was investigated individually in immortalized non-transformed normal oral keratinocytes 
(NOK). These cells were chosen because they are natural targets of HPV infection and 
can be transformed by HPV 16 (Park, Min, Li, Huang, & Doniger, 1991). 
The E6* and full-length E6 isoforms tagged with the Flag epitope were cloned 
into the pLNCX retroviral vector. NOK immortalized by hTert expression (Piboonniyom 
et al., 2003) were then infected with the retroviral stocks (pLNCX (control), pLNCX-E6* 
and pLNCX-E6), and several stable cell lines were obtained for each isoform. The level 
of ROS was measured in 2 cell lines expressing pLNCX-E6* (1and 5) and in 2 cell lines 
expressing pLNCX-E6 (1 and 3), and compared to that seen in control pLNCX cells. 
Figure 4A shows the flow cytometry results following DCFDA staining in these cells. 
Figure 4B shows PCR data confirming the expression of E6L and E6* in the NOK stable 
cell lines. Representative cell lines (NOK pLNCX, NOK pE6* 1 and NOK pE6 5) were 
chosen, and the experiment was then repeated three times following DCF and DHE 
staining to generate the bar graphs shown in Figure 4C. qRT-PCR data (Figure 4D) and 
immunoblot (Figure 4E) confirmed the higher level of E6 isoform expression in the 
selected NOK clones. Overall, NOK cells expressing E6* displayed higher levels of ROS 
compared to NOK cells expressing the empty vector pLNCX. In contrast, NOK cells 
expressing the full-length isoform demonstrated no significant change relative to control 
cells.  
 
44 
 
 
 
 
 
 
 
45 
Superoxide Dismutase and Glutathione Expression Levels Decrease 
with E6* Expression 
A number of factors may contribute to the observed increase in cellular ROS 
following E6* expression. One possibility is that E6*-expressing cells possess a reduced 
antioxidant capacity, thereby allowing ROS levels to increase due to the cell’s reduced 
ability to adequately dispose of them. To determine whether decreases in the cellular 
antioxidant capacity might contribute to E6*-mediated increases in ROS, we examined 
the expression of two important antioxidant enzymes, superoxide dismutase (SOD) and 
glutathione peroxidase (Gpx). SOD can be expressed as three isoforms, SOD1, SOD2 
and SOD3. Of the three, only SOD1 and SOD2 are intracellular, and were therefore 
chosen for analysis. 
We observed that SiHa and CaSki cells differed not only in ROS but also in the 
levels of expression of antioxidant proteins (Figure 5A). In particular, ROS levels are 
higher, while expression of the antioxidant enzymes SOD2 and Gpx1/2 was lower in 
CaSki as compared to SiHa cells. To further investigate the relationship between 
antioxidant expression levels and E6 isoform expression, we repeated these experiments 
in the NOK system. Consistent with our findings in the cervical cancer cell lines, we 
observed a distinct reduction in SOD2 expression in NOK pLNCX-E6* cells as 
compared to the control (NOK pLNCX), while no change was detected in SOD 1 levels. 
Furthermore, NOK cells expressing E6* displayed lower levels of Gpx expression 
(Figure 5B). In contrast, NOK cells expressing the full-length isoform, pLNCX-E6, did 
not display significantly changed levels of these proteins. The data described above 
suggests that E6* may have the ability to affect the levels of SOD2 and/or Gpx 1/2 and 
that this in turn affects the levels of ROS in these cells. To further explore this possibility, 
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we asked whether decreases in the expression of antioxidant enzymes such as SOD2, 
would also lead to increased ROS levels in NOK cells. NOK cells were transiently 
transformed with either siControl or siSOD2 siRNA for 72 h. Cells were then collected, 
and either stained with DCF to detect ROS or used to prepare protein lysates for the 
detection of SOD2 levels. Figure 5C demonstrates a decrease in SOD2 expression in 
siSOD2 NOK cells compared to siControl, and Figure 5D shows that this decrease in 
SOD2 resulted in an increase in ROS levels in NOK siSOD2 cells. Together, these 
findings support the idea that lower expression of antioxidant proteins may contribute to 
the higher ROS levels observed in E6*-expressing cells. 
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E6* Expression Results in Higher Levels of DNA Damage in Both 
Cervical and NOK Cell Lines 
The results described above demonstrate that E6* expression leads to an increase 
in ROS and a decrease in the level of at least two antioxidant enzymes, SOD2 and GPX. 
Both findings point toward the induction of oxidative stress as a result of E6* expression. 
Oxidative stress, in turn, is known to induce DNA damage. To determine whether E6* 
expression also increases DNA damage, we employed two assays: the comet assay 
(Sigma-Aldrich), which detects single strand DNA breaks, and the flow cytometric 
OxyDNA assay (Calbiochem), which measures the levels of 8-oxoguanine, one of the 
most common oxidative stress base modifications in cells (Grollman & Moriya, 1993). 
Figure 6A (upper panel) demonstrates the effect of incremental increases in DNA 
damage on comet appearance in control cells following alkaline electrophoresis. The 
lower panel shows a representative comet assay performed on NOK cells transfected with 
the empty vector, E6* or E6. When CaSki and SiHa cells were analyzed using the comet 
assay, the results (Figure 6B), showed that CaSki cells, with their higher level of 
oxidative stress, sustained a higher level of DNA damage than did SiHa cells. This is 
consistent with a model in which the observed increase in oxidative stress corresponds to 
downstream changes in the level of DNA damage. An alternative method of determining 
DNA damage is to assess the levels of 8-oxoguanine, since this is the most commonly 
modified base. The OxyDNA assay results for the cervical cancer cells CaSki and SiHa 
(Figure 6C) reflected the results of the comet assay, namely, that CaSki cells exhibited a 
higher level of DNA damage than did the SiHa cells.  
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To determine whether increased E6* expression can also lead to DNA damage in 
non-transformed cells, comet and OxyDNA assays were performed on the NOK pLNCX, 
NOK pLNCX-E6*, and NOK pLNCX-E6 cell lines. We observed (Figures 6D and 6E) 
that for both assays, pLNCX-E6* cells displayed a higher level of DNA damage than did 
either the control (NOK pLNCX) or the pLNCX-E6 cells. Taken together, these findings 
indicate that E6* expression in cells can lead both to increased levels of ROS and to a 
corresponding increase in oxidative DNA damage.  
Poly [ADP-ribose] polymerase 1 (PARP) is an enzyme that ADP-ribosylates 
nuclear proteins and is involved in the repair of DNA breaks. Therefore, we used it as an 
indirect marker of DNA damage to validate our findings (Huber, Bai, de Murcia, & de 
Murcia, 2004). Our data revealed higher levels of PARP1 expression in CaSki (Figure 
7A) than in SiHa, and in NOK pLNCX-E6* cells compared to NOK pLNCX or NOK 
pLNCX-E6 cells.  
If E6* causes oxidative damage leading to DNA damage, we would predict that 
over-expression of E6* in SiHa cells would result in an increase in DNA damage. 
Analyzing the levels of 8-oxoguanine in SiHa pE6* as compared to SiHa pFlag control 
cells confirmed this expectation (Figure 7C). Consistent with these findings, SOD2 levels 
were lower in the SiHa pE6* cells than in the SiHa pFlag control cells (Figure 7D).  
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Discussion 
In this study, we demonstrated that expression of E6*, the truncated splice variant 
of the HPV 16 E6 protein, can increase ROS levels in host cells. This may be due to 
decreased expression of anti-oxidant enzymes, and leads to downstream DNA damage. 
The generation of oxidative stress during a viral infection is a common occurrence during 
the inflammatory response to infection, due to the release of ROS from neutrophils and 
macrophages during the “oxidative burst”. In addition, activated phagocytes release pro-
oxidant cytokines. RNA viruses such as influenza A and members of the 
paramyoxoviridae family have been shown to activate monocytes and 
polymorphonuclear leukocytes, which respond to infection with a respiratory burst and 
generate ROS. However, some viruses such as HPV, EBV and HBV are weakly 
immunogenic, and do not necessarily induce a pronounced inflammatory response 
(Levitsky & Masucci, 2002; Tindle, 2002; Wieland & Chisari, 2005). Interestingly, 
oxidative stress plays a significant role in viral pathogenesis in these infections as well. 
Several groups have demonstrated that HBV can induce oxidative stress both in vivo in 
mice in and in vitro in cells (Ha, Shin, Feitelson, & Yu, 2010). The Human hepatitis virus 
x protein targets the mitochondria to alter membrane potential and increase endogenous 
ROS levels, while HBV infected cells carrying the HBV pre-S mutant exhibited 
enhanced levels of ROS and oxidative DNA damage through endoplasmic reticulum 
stress pathways (Wang, Huang, Lai, & Su, 2006). Although the significance of oxidative 
stress in the context of the viral life cycle has not been elucidated in each of these cases, 
biologically-significant effects of these increases in oxidative stress have been well-
documented. 
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E6/E7 mRNA from high-risk HPV types undergoes alternate splicing to produce 
an E6* transcript, which is often the most prevalent species found both in cervical tumors 
and in the early stages of HPV infection. Here, we present data demonstrating that the 
E6* isoform present in high risk HPV types increases oxidative stress in both HPV+ 
(Figures 1 and 2)  and HPV- (Figures 3 and 4) cell lines. In contrast, the full-length 
isoform, E6, displayed no significant effect on ROS.  
Reactive oxygen species (ROS) and antioxidants exist in a delicate balance in 
cells. Oxidative stress occurs when this balance is disrupted due to either an increase in 
ROS production, a decrease in cellular antioxidant levels, or both (Sies, 1997b). The 
reactive oxygen species released during oxidative stress have the ability to directly 
damage DNA. (Kawanishi et al., 2001). One reactive oxygen species in particular, the 
highly reactive hydroxyl radical, interacts with DNA directly, damaging both purine and 
pyrimidine bases (Dizdaroglu et al., 2002). The reaction of the hydroxyl ion with 
guanine, the most easily oxidized base, leads to formation of the most common base 
modification, 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) (Kawanishi et al., 2001; 
Steenken & Jovanovic, 1997). In addition to creating modified bases, ROS-induced DNA 
damage leads to single and double strand breaks, abasic sites and DNA cross-linking 
(Demple & Harrison, 1994; Marnett, 2000). This damage to DNA may lead to mutations, 
aberrations and genomic rearrangements. Consistent with these observations, our data 
shows that DNA damage is highest in HPV+ cells with higher relative E6* expression 
(Figure 6B and 6C), as well as in NOK cells expressing E6* (Figure 6D and 6E).  PARP, 
a cellular marker of DNA damage was also increased in CaSki cells compared to SiHa 
54 
cells, and in NOK E6* compared to NOK pLNCX and NOK pLNCX-E6 cells, further 
validating our data showing that DNA damage is higher in these cell lines (Figure 7). 
One of the mechanisms by which cells can counteract the effects of increased 
oxidative stress is through the expression of antioxidant enzymes. Endogenous ROS 
originates from the mitochondria, cytochrome P450 metabolism, peroxisomes, and 
inflammatory cell activation (Inoue et al., 2003). Among these, the mitochondria are the 
primary source of the free radicals hydrogen peroxide and superoxide in cells. Since 
mitochondrial oxidative phosphorylation is the major source of free radical generation, 
mitochondria are enriched with antioxidant enzymes such as SOD and Gpx (Cadenas & 
Davies, 2000; F. â. M. Yakes & Vanâ€‰Houten, 1997). In this report, we demonstrate 
that changes in cellular ROS are associated with changes in the expression of antioxidant 
enzymes such as SOD2 and Gpx (Figures 5 and 7D). Events that cause a decrease in 
SOD are predicted to result in an increase in the levels of ROS.  We found that 
expressing E6* in NOK cells resulted in both a decrease in SOD2 expression and a 
corresponding increase in ROS (Figures 4 and 5). In addition, CaSki cells displayed 
lower levels of SOD2 than did SiHa cells, and these lower levels of SOD2 were 
associated with higher levels of ROS (Figures 1 and 5). Gpx also functions in antioxidant 
defense, and its inhibition results in an increase in the level of cellular ROS as well 
(Valko et al., 2006a).  Our findings with Gpx mirror those of SOD2, with an increase in 
E6* leading to a decrease in Gpx and an increase in ROS (Figures 1, 4, and 5). 
Expression of antioxidant enzymes is regulated by several transcription factors including 
AP-1, SP-1, Nf-κB, p53, and NRF2 among others (Dhar, Young, & Colburn, 2002; Surh, 
2005). It is possible that E6* may modulate the expression of antioxidant enzymes either 
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directly or indirectly by influencing transcriptional factor expression or activity. 
However, this question requires further investigation. 
In conclusion, we have now demonstrated that expression of the HPV 16 E6* 
isoform increases oxidative stress and induces oxidative DNA damage in host cells. The 
significance of this increase in ROS to the HPV virus life cycle requires further 
exploration. Presently, we can only speculate that this increase in ROS and oxidative 
DNA damage may contribute to viral genome production. Recent studies suggest that the 
introduction of double strand DNA breaks into HPV DNA during productive replication 
is an important step in HPV genome amplification and genome maturation (Gillespie, 
Mehta, Laimins, & Moody, 2012). Studies have also shown that exposure of cells that 
normally maintain episomal copies of the HPV genome to physiologically high doses of 
nitric oxide can lead to up-regulation of early E6 and E7 oncogene expression, as well as 
to a significant increase in DNA double strand breaks (Wei et al., 2009). This increased 
oxidative stress likely plays a role in HPV-mediated carcinogenesis. For example, studies 
in W12 cells demonstrated that increased DNA double-strand breaks are associated with 
HPV 16 integration in cervical keratinocytes (D. M. Winder et al., 2007). In addition, 
ROS-induced DNA damage results in single and double strand breaks, abasic sites, 
modified bases and DNA cross-linking (Demple & Harrison, 1994; Marnett, 2000). 
Interestingly, expression of the E6* variant of E6 coincides with E7 expression during the 
early stages of HPV infection, and has been demonstrated to be the most prevalent 
species in cervical tumors (Heer et al., 2011), suggesting that a clear understanding of its 
activities and roles is likely to contribute to our understanding of both the virus life cycle 
and to carcinogenesis. With this study, we have now demonstrated a link between E6* 
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expression and oxidative stress in cells, by showing that E6* expression can increase 
ROS levels, resulting in increased levels of DNA damage. Further work will focus on the 
impact of this E6*-mediated oxidative stress on the virus life cycle and carcinogenesis. 
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CHAPTER THREE 
IDENTIFICATION OF PATHWAYS INVOLVED IN ROS 
REGULATION AND DNA DAMAGE 
 
Introduction 
 
High Risk types of Human Papillomavirus (HPV) are the causative agents of most 
cases of cervical cancer as well as a significant proportion of oropharyngeal and other 
anogenital cancers. High-risk types of the virus encode two viral oncogenes, E6 and E7, 
that respectively are responsible for degrading the cellular proteins p53 and 
retinoblastoma (pRB) and for inducing cell transformation (Munger et al., 2004). In HPV 
16 and HPV 18, the two types most frequently involved in cervical cancer, these two 
viral oncogenes are transcribed as a single bicistronic E6E7 transcript using a common 
promoter and a common early polyadenylation site (Tang, Tao, McCoy, & Zheng, 2006). 
This bicistronic E6E7 pre-mRNA contains three exons and two introns (Tang et al., 
2006). Intron 1 is positioned in both the HPV 16 E6 and the HPV 18 E6E7 pre-mRNAs, 
and is efficiently spliced in these high-risk strains to produce the E6*I spliced transcript 
(J. Doorbar et al., 1990; Zheng, Tao, Yamanegi, Bodaghi, & Xiao, 2004). This splicing 
pattern appears to be a unique characteristic of all high-risk HPV types, as it is not 
confined to HPV 16 and HPV 18. In fact, the high-risk types HPV 16, HPV 18, HPV 31, 
HPV 33, and HPV 45, which together are responsible for almost all cases of cervical 
cancer, all display the ability to produce these variants. In contrast, the low-risk types 
HPV 6 and HPV 11 do not demonstrate this ability (Naucler et al., 2007). 
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The function and activities of the full-length E6 isoform have been intensively 
studied over the last two decades, and several excellent reviews have been published that 
detail its functions and activities (Howie et al., 2009; Cary A. Moody & Laimonis A. 
Laimins, 2010; S. Tungteakkhun & P. Duerksen-Hughes, 2008). In contrast, 
comparatively little is known of the activities of the E6* isoform, and its significance in 
both the viral life cycle and in carcinogenesis has been disputed. However, several sets of 
data suggest that the E6* isoform modulates the activity of the full-length E6, and that it 
may also possess activities that are independent of E6. For instance, we observed that 
overexpression of E6* in SiHa cells sensitized these cells to both TNF and Fas-induced 
apoptosis (M. Filippova et al., 2009). We also showed that full-length E6 and E6* bind to 
different regions on procaspase 8. E6 large binding leads to accelerated degradation of 
procaspase 8, while E6* binding leads to protein stabilization (Tungteakkhun et al., 
2010). Work done by the Banks group has shown that the HPV18 E6* protein regulates 
the ability of the full-length isoform to degrade p53, with an inverse relationship 
observed between the level of E6* and the ability of full-length E6 to degrade p53. Taken 
together, these observations suggest that E6* possesses important and distinct functions 
from those of the full-length E6 isoform. A 2014 paper from our lab has also shown 
novel independent activities for the E6* isoform. In this report, we demonstrated for the 
first time that HPV 16 E6* can increase ROS levels and DNA damage in both HPV 
positive and HPV negative cells (Williams, Filippova, Filippov, Payne, & Duerksen-
Hughes, 2014). This ability is anticipated to have potential significance for HPV-
mediated carcinogenesis, since DNA damage sites may facilitate HPV integration 
(Williams et al., 2011).   
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To investigate the pathways involved in ROS regulation that may be influenced 
by HPV 16 E6 isoform expression, we employed the cervical cancer cell lines CaSki and 
SiHa. We chose these two lines because we had previously demonstrated that they 
express significantly different ratios of the E6 splice variants, such that the CaSki cells 
have a higher E6*/E6 ratio than do the SiHa cells. This higher E6*/E6 ratio is reflected in 
the higher ROS levels observed in CaSki cells (Figure 1). We used these cells to 
determine what pathways are likely to contribute to the differences in ROS profiles 
observed in these cells by employing a proteomic analysis to identify several pathways in 
which protein expression differed significantly between CaSki and SiHa cells. Our 
findings revealed that some of the identified pathways were those involved in ROS 
regulation. Differential expression of several of the identified proteins was then validated 
by immunoblot.  To complement this protein-level data, a PCR microarray approach was 
employed to identify several genes involved in ROS metabolism that differed in 
expression between the two cell lines. We found that expression of pro-oxidant genes 
such as OXR1 were down-regulated in SiHa versus CaSki cells, while antioxidant genes 
such as SOD2 were up-regulated. Several of these microarray findings were then 
validated by RT-PCR. Together, these protein- and gene expression- datasets may 
explain the observation that SiHa cells display lower levels of ROS than do CaSki cells.  
 
 
Results 
 
ROS Levels are Higher in CaSki than in SiHa Cells 
 
Our initial studies exploring the difference in ROS levels in cervical cancer cell 
lines were done using CaSki and SiHa cells, which are well-known cellular models of 
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cervical cancer derived from HPV 16+ cervical carcinomas. These two cell lines differ in 
the ratio of expression of the two E6 isoforms, in that the ratio of E6* expression to E6 
full-length expression is significantly higher in CaSki than in SiHa cells (Figure 1A). 
This is consistent with our previously published data, where we demonstrated through 
quantitative PCR that while the level of expression of full length E6 is similar in both 
CaSki and SiHa cell lines, the level of expression of E6* is much higher in CaSki than in 
SiHa cells (Williams et al., 2014). We began by estimating the ROS level in SiHa and 
CaSki cells. ROS levels in SiHa and CaSki cells were estimated using flow cytometry 
following staining with the fluorescent dyes 5-(and-6)-carboxy-2',7'-dichlorofluorescein 
diacetate (DCF) (detects hydrogen peroxide, hydroxyl and peroxyl redicals) and 
dihydroethidium (DHE) (Peshavariya et al., 2007) (detects superoxide radicals). The flow 
cytometry results clearly demonstrated that the levels of both species were higher in 
CaSki cells than in SiHa cells (Figure 1B and 1C).  
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Proteomic Analysis Identified Differences in Pathways Connected to 
p53 Activation, Mitochondrial Function and Oxidative Stress 
To identify the pathways responsible for the different ROS profiles observed in 
CaSki versus SiHa cells, we performed a comparative proteomic analysis. Identification 
and quantification of proteins was done by simultaneously running TMT-labeled 
trypsinized CaSki and SiHa lysates through an LTQ-Orbitrap mass spectrometer. The 
total number of proteins in which the level of expression between SiHa and CaSki cells 
differed by more than 1.5-fold was 430 (data not shown), and the detected range of 
differences in protein levels between these cells ranged from -6.0 to 6.9 fold. Seventy-six 
of these proteins were found to be up-regulated, while the remaining proteins were down-
regulated in SiHa cells as compared to CaSki cells. 
To gain insight into the functions of these differentially expressed proteins, we 
utilized the online IPA analysis (Ingenuity Systems) tool to group them into functionally 
related networks and pathways.  Figure 2 summarizes 9 of the functions for which protein 
expression differs most between these two lines. Some of the more remarkable 
differences in protein levels between SiHa and CaSki cells were detected in proteins 
involved in mitochondrial functions such as mitochondrial depolarization, swelling of 
mitochondria, and the biogenesis of mitochondria (Figure 2). The involvement of the 
mitochondria is significant since the Electron Transport Chain (ETC) is found in the 
inner mitochondrial membrane. The ETC is the major source of premature leakage of 
electrons to oxygen, leading to the formation of superoxide species that can give rise to 
other reactive oxygen species and possibly oxidative stress. Another group of pathways 
differentially activated between these cell lines is connected to DNA repair and the DNA 
damage response (Figure 2). Differences in the expression of proteins involved in 
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mitochondrial status and DNA repair were accompanied by changes in the levels of 
proteins involved in the regulation of ROS levels (Figure 2). For example, NAD(P)H 
dehydrogenase, quinine 1 (NQO1), peroxiredoxin 2 (PRDX2) and superoxide dismutase 
1 (SOD1), which are responsible for inactivation of superoxide radicals, were found in 
higher levels in SiHa than in CaSki cells (data not shown).  
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Genes Involved in ROS Metabolism and Homeostasis are Up-
Regulated in SiHa as Compared to CaSki Cells 
To further explore the idea that ROS-related genes are expressed differentially 
between SiHa and CaSki cells, we employed the Human Oxidative Stress and 
Antioxidant Defense PCR Array (SA Biosciences), which profiles the expression of 84 
genes related to oxidative stress. We found that several of these genes were up-regulated 
in SiHa (as compared to CaSki) cells, and that a few were down-regulated (Table 1). 
Genes whose expression was consistently down-regulated in SiHa (relative to CaSki) 
cells included aldehyde oxidase 1 (AOX1), NADPH oxidase complex (NCF2), and 
oxidation resistance protein (OXR1); these proteins are responsible for the production of 
reactive oxygen radicals. To validate the differences identified by the PCR microarray 
between these two cell lines with regards to expression of proteins involved in ROS 
metabolism, we evaluated the expression levels of a subset of the proteins involved in 
antioxidant defense by immunoblot (Figure 3A). Consistent with our PCR microarray and 
proteomic data, the immunoblot analysis confirmed higher levels of SOD1, SOD2 and 
glutathione peroxidase 1/2 (Gpx1/2) in SiHa cells compared to CaSki cells. A reduced 
level of OXR1 expression in SiHa cells as compared to CaSki cells was also confirmed 
by immunoblot (Figure 3A). Genes that were up-regulated in SiHa (Table 1) participate 
in ROS metabolism in various ways. For example, cytochrome b-245, alpha polypeptide 
(CYBA) is a component of mitochondrial Complex III, which is involved in the transfer 
of electrons to Complex IV so that water can be formed. Other genes belong to various 
antioxidant systems. For example, SODs, GPXs and PRDXs catalyze reactions that 
inactivate superoxide radicals (SODs) or H2O2 (GPXs and PRDXs). Semi-quantitative 
RT-PCR (Figure 3B) along with quantitative qRT-PCR (Figure 3C) were also used to 
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confirm certain results of the PCR array profiles. Overall, our data demonstrated 
significant differences between SiHa and CaSki cells with regards to the expression 
levels of genes and proteins involved in ROS metabolism and homeostasis. We observed 
that antioxidant levels are generally higher in SiHa as compared to CaSki cells while pro-
oxidant levels were lower.. Consistent with these results, PARP1 expression, a marker of 
DNA damage caused by oxidative stress, was also detected at a higher level in CaSki 
than in SiHa cells as assessed both by proteomic analysis (data not shown) and by 
immunoblot analysis (Figure 3A). 
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Materials and Methods 
Reagents 
Monoclonal α-NQO1, α-OXR1 and α-β-actin were obtained from Sigma-Aldrich, 
monoclonal α-SOD1 and α-GPX 1/2 from Santa Cruz Biotechnology, monoclonal α -
SOD2 from BD Biosciences, and monoclonal α-PARP1 (Ab-2) from Millipore 
Corporation (Calbiochem). Fetal Bovine Serum (FBS) was obtained from Life 
Biosciences. 
Cell Culture 
CaSki and SiHa cells (derived from human cervical carcinomas) were obtained 
from the ATCC (Manassas VA). All cells were cultured in modified Eagle medium 
(MEM) (CellGro). The medium was supplemented with 10% fetal bovine serum (Life 
Biosciences) and with penicillin (100 u/ml) and streptomycin (100 µg/ml) (Sigma-
Aldrich).  
Proteomics Analysis 
SiHa and CaSki cells (107) were lysed in RIPA lysis buffer (Sigma-Aldrich) and 
sonicated.  Cleared lysates were denatured, reduced, and alkylated as recommended by 
the TMT Mass Tagging Kit (Thermo Fisher Scientific) protocol.  Trypsin was added at a 
protein/enzyme ratio of 30:1 by mass, and the digestion was performed at 37°C 
overnight. Peptides were labeled with TMT (tandem-mass-tagging) reagents according to 
the manufacturer’s protocol in duplicate, and equal amounts of labeled peptides were 
combined to obtain one sample, which was separated into 9 fractions by strong cation 
exchange chromatography using TopTip columns (PolyLC). Elution was performed with 
increasing concentrations of KCl (from 0 to 0.5 M). Eluates were dried using a 
SpeedVac, then desalted using C18/hypercarb TopTip columns (PolyLC). Samples from 
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each fraction were run in triplicate on an Orbitrap Pro mass spectrometer that was 
coupled with a nanoLC (ThermoFisher), and the spectra obtained were analyzed with 
Proteome Discoverer 1.3 software against the Human International Protein Index (IPI) 
database. Peptides were identified with a FDR (False Discovery Rate) of less than 1%.  
Proteins were considered differentially expressed if the fold ratio was more than 1.5. 
Protein data were further analyzed using Ingenuity Pathway Analysis (IPA) software to 
identify differences in pathways and networks between cell lines.  
 
Measurement of ROS in Cells by Flow Cytometry 
Intracellular generation of hydrogen peroxide (H2O2), hydroxyl and peroxyl 
radicals (DCFDA) and superoxide (O2−) (DHE) was estimated using either the 5-(and-
6)-Carboxy-2',7'-Dichlorodihydrofluorescein diacetate (DCF) or Dihydroethidium (DHE) 
membrane permeable probes (Life Biosciences). Reagents were diluted into culture 
media, and then added to cells to a final concentration of 10 µM. After treatment, the 
cells were collected in 1X PBS and analyzed using the Becton-Dickinson FACSCalibur 
flow cytometer (Becton-Dickinson, San Francisco, CA). DCF was detected in the FL-1 
channel, while DHE was detected in the FL-2 channel. Data was collected in log scale 
and analyzed using Flow-Jo software.  
 
Immunoblot Assays 
For immunoblot analysis, 106 cells were lysed in 100 µl of Laemmli lysis buffer, 
and lysates were sonicated and separated by SDS-PAGE. After the transfer of protein 
onto Immobilon P membranes (Millipore Corporation) and blocking of the membrane 
with 1% bovine serum albumin dissolved in TBST, primary antibodies were applied 
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overnight.  Secondary ImmunoPure antibody (α-mouse or α-rabbit), conjugated with 
horseradish peroxidase (ThermoFisher), was applied onto the membrane for 1 h, and the 
detection of signal was performed using the chemiluminescent SuperSignal West Dura or 
Pico maximum-sensitivity substrate (ThermoFisher). 
 
RNA Isolation, RT-PCR and qRT-PCR 
Cells were plated in a 10 cm tissue culture plate and allowed to grow to semi-
confluency. RNA was isolated using Tri Reagent according to the manufacturer’s 
protocol (Sigma-Aldrich). cDNA was synthesized using ImPromII reverse transcriptase 
(Promega) and an oligo(dT) primer. Primers for the 5’ and 3’ ends of the indicated genes 
were used to amplify PCR products. 
Quantitative qRT-PCR was conducted using the Absolute QPCR Sybr green kit 
according to the manufacturer’s protocol (ABgene). The observed gene concentrations 
were normalized using PGK1 expression levels.  
 
Oxidative Stress and Antioxidant Defense PCR Array 
 
The PCR Microarray was performed according to the manufacturer’s instructions 
(SABiosciences, a QIAGEN company, Valencia CA). Gene expression was compared 
according to the CT value. Normalization was performed for each cDNA sample using 
the average of five housekeeping genes provided by manufacture. 
 
Statistics 
 
All assays were repeated at least three times, and the results reported as mean ± 
standard deviation. Differences were analyzed by the Student’s t-test. P≤0.05 was 
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regarded as significant. 
  
Discussion 
Oxidative stress has been found to be a contributing factor in cancer 
tumorigenesis across a wide spectrum of cancers (Klaunig et al., 1995; Klaunig et al., 
1998; Toyokuni, 2008). Oxidative stress occurs when the balance between reactive 
oxygen species (ROS) and cellular antioxidants is perturbed, a common occurrence in 
cancer (Sies, 1997a). The free radicals thus generated are capable of activating 
procarcinogens, altering the level of cellular antioxidant enzymes, and causing damage to 
DNA and other biomolecules (Sun, 1990). ROS-induced DNA damage results in single 
and double strand breaks, abasic sites, modified bases and DNA cross-linking (Demple & 
Harrison, 1994; Marnett, 2000). This oxidative damage to DNA can then result in 
chromosomal alterations that lead to cell transformation (Mani & Chinnaiyan, 2010). As 
may be expected, the antioxidant enzyme system is found to be perturbed in cancer. For 
example, the antioxidant enzyme, manganese superoxide dismutase (Mn-SOD), in 
particular, is thought to function as a tumor suppressor (Bravard et al., 1992) as its 
expression is found to be decreased in some transformed cell lines (Westman & 
Marklund, 1981). Additionally, low activities of other cellular antioxidant enzymes such 
as copper/zinc superoxide dismutase (CuZnSOD), catalase and glutathione peroxidase 
1(Gpx1) are often observed in transformed cell lines (Li, Oberley, St Clair, Ridnour, & 
Oberley, 1995). These findings correlate with the idea that oxidative stress functions as a 
co-factor in carcinogenesis.  
CaSki and SiHa cells are both HPV-16 transformed cervical cancer cell lines. In a 
previous study, our laboratory demonstrated that the level of ROS as well as that of the 
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antioxidant enzymes superoxide dismutase and glutathione peroxidase was significantly 
different between these two cell lines (Williams et al., 2014). Specifically, CaSki cells 
displayed higher levels of ROS and lower levels of antioxidant enzymes than did SiHa 
cells. One consequence of the higher levels of ROS in CaSki cells was a higher level of 
DNA damage. Further experiments employed NOK cells stably expressing only one of 
the two isoforms (E6 or E6*) to investigate the effect of the HPV 16 E6 isoforms 
individually. These experiments revealed that expression of E6*, but not E6, increased 
the levels of ROS and oxidative DNA damage in these NOK cells. These findings are 
consistent with those from the cancer cell lines, since CaSki cells had a higher E6*/E6 
ratio, higher ROS levels, and more oxidative DNA damage than did the SiHa cells.   
In the present study, we sought to identify those pathways and possibly individual 
genes involved in ROS regulation in CaSki and SiHa cells that may be influenced by 
HPV 16 E6.  Because previous studies in our lab demonstrated that E6* is responsible for 
the increasing ROS in cells, we postulated that the differences indentified in pathways 
and gene expression between these cell lines may be due to the difference in E6*/E6 
expression. The major source of ROS production in cells is the mitochondria, where 
enzymes involved in the electron transport chain and the production of superoxide are 
located (Balaban, Nemoto, & Finkel, 2005). ROS-producing enzymes identified in the 
present study were expressed at higher levels in CaSki cells (Table 1), consistent with the 
higher levels of ROS observed in these cells. On the other hand, the expression of 
proteins with antioxidant functions was higher in SiHa than in CaSki cells. Examples of 
such antioxidant enzymes include SOD1, SOD2, NQO1, PRDX and GPX (Figure 3 and 
Table 1). Together, these differences in gene and protein expression may result in 
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downstream changes in the level of cellular levels of ROS as measured by flow 
cytometry (Figure 1B and 1C). Furthermore, these differences were also reflected in the 
difference in levels of expression of proteins involved in DNA damage recognition and 
response (Figure 3A), since these processes are activated during oxidative stress (Altieri, 
Grillo, Maceroni, & Chichiarelli, 2008; Kryston, Georgiev, Pissis, & Georgakilas, 2011). 
However, while these results provide a starting point for examining the influence of these 
HPV 16 E6 isoforms on ROS, the fact that multiple copies of multiple viral genes, which 
are also expressed at different levels, are present in these cells, combined with the lack of 
matched controls, complicate the analysis of data from these cells and required the use of 
another model system. Therefore, future studies will employ NOK cells that stably 
express the different E6 isoforms separately to determine the individual effect of each 
isoform on the pathways identified in CaSki and SiHa cervical cancer cells. 
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CHAPTER FOUR 
DISCUSSION 
 
Summary of Findings 
High Risk strains of Human Papillomavirus (HPV) are the causative agents of 
most cases of cervical cancer as well as a significant proportion of oropharyngeal and 
other anogenital cancers. The burden of cervical cancer has declined in recent decades 
due to the efficiency of screening with the Pap smear, and is expected to decline even 
further within the next few decades due to the influence of the HPV vaccines. However, 
the incidence rate of other HPV-related cancers such as anal, oropharyngeal and vulvar 
cancers has steadily increased within that same period. In addition, vaccine uptake rates 
in the US remain at startling low levels (~33%) as compared to that seen in other first 
world countries such as Canada, where vaccine uptake is as high as 75%in some regions 
(Musto et al., 2013). This limits the expected influence of the vaccine on cervical cancer 
incidence in upcoming decades. Treatment options for cervical cancer remain inadequate, 
as one third of patients with invasive cervical cancer die from either recurrent or 
metastatic disease (Tao, Hu, Ramirez, & Kavanagh, 2008).  Each of these factors 
underscores the need for ongoing research into the mechanisms behind HPV-related 
carcinogenesis. 
The experiments described in chapter two we present data demonstrating that the 
E6* isoform of HPV 16 is able to increase ROS levels in cells, thereby causing increased 
oxidative stress and DNA damage in these cells. In contrast, expression of the full-length 
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isoform, E6L, displayed no significant effect on ROS. In this report, we also demonstrate 
that changes in cellular ROS are associated with changes in the expression of antioxidant 
enzymes such as SOD2 and Gpx (Figure 5). PARP, a cellular marker of DNA damage in 
cells was also increased in CaSki cells as compared to SiHa cells, and in NOK E6* 
compared to NOK pLNCX and NOK E6 cells. These findings are consistent with our 
data showing that DNA damage is higher in E6*-expressing cell lines (Figure 6). 
Superoxide dismutases are essential enzymes that eliminate superoxide radicals by 
converting them to hydrogen peroxide (reviewed in (McCord & Edeas, 2005)). 
Therefore, events that cause a decrease in SOD are predicted to result in an increase in 
superoxide. Consistent with this prediction, we found that expressing E6* in NOK cells 
resulted in both a decrease in SOD2 expression and an increase in ROS (Figures 5 and 4). 
In addition, CaSki cells displayed lower levels of SOD2 than did SiHa cells, and these 
lower levels of SOD2 were associated with higher levels of ROS (Figures 5 and 1). To 
the best of our knowledge, this is the first study demonstrating a link between E6* 
expression and oxidative stress in cells. These findings are significant, as they suggest 
that HR HPV E6* may serve a significant role in generating oxidative DNA damage, and 
that this increased oxidative stress may facilitate HPV-mediated carcinogenesis. 
In chapter three, we observed differences in the ROS profiles of the cervical 
cancer cell lines CaSki and SiHa. Therefore, in chapter three we asked which pathways 
involved in ROS regulation might be influenced by the differential expression of the 
HPV 16 E6 isoforms in these cells. Proteomic analysis enabled the identification of 
several differentially-activated pathways that were involved not only in ROS regulation 
but also in p53 activation and mitochondrial functioning. PCR analysis of an array of 
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genes involved in ROS regulation then confirmed the differences in the expression levels 
of several of the associated genes. We observed that in CaSki cells, as compared to SiHa 
cells, several pro-oxidant genes such as AOX1 and OXR1 were up-regulated, while 
antioxidant genes such as SOD1 and SOD2 were down-regulated. Further investigation 
of these expression levels by immunoblotting and qRT-PCR validated our initial findings. 
This data agrees with our earlier observation of increased ROS levels in CaSki versus 
SiHa cells, since increased pro-oxidant and decreased antioxidants levels would lead to 
the downstream observation of increased ROS levels. 
 
Conclusions 
Previous research has shown that expression of the high-risk HPV16 E6 oncogene 
results in a greater frequency of foreign DNA integration into the host genome as 
compared to expression of the low risk HPV E6 genes (Kessis, Connolly, Hedrick, & 
Cho, 1996).  As has been shown in studies of hepadnavirus, sites of DNA damage can 
serve as sites for viral DNA integration, a critical step in carcinogenesis (S. Jeon & P. 
Lambert, 1995; Petersen et al., 1997). Therefore, it is reasonable to expect that the 
integration of HPV viral DNA into that of the host would also be enhanced by damage to 
both the viral episome and the host DNA, as this would create a site for integration. 
Studies such as those noted above and other similar findings led to our initial hypothesis 
that expression of HPV 16 E6* may increase ROS levels in cells and lead to increased 
levels of DNA damage in cells. Interestingly, only high-risk strains of HPV express the 
E6* splice variant. With these facts in consideration, two questions were posed at the 
beginning of these studies. 1) Does E6 isoform expression affect the level of cellular 
oxidative stress in cells, and if so, what is/are the molecular mechanism(s)? This question 
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was addressed in chapters 2 and 3. 2) Does expression of either of the E6 isoforms affect 
the level of DNA damage in cells? This question was answered in chapter two.  
In summary, the results from the experiments described in this dissertation show 
for the first time that an HPV oncogene, E6*, can increase ROS levels in cells, decrease 
expression of antioxidant enzymes and induce an increase in oxidative DNA damage. 
They also show that in the CaSki and SiHa cervical cancer cell lines, difference in ROS 
levels are reflected in differences observed in pathways connected to oxidative stress, as 
identified at the protein level by proteomic analysis, IPA and immunoblotting, and at the 
gene expression level by the Human Oxidative Stress and Antioxidant Defense PCR 
Array and validated by RT PCR. Therefore, the overall findings of this study state that 
HPV 16 E6* expression increases oxidative stress and DNA damage in cells though 
pathways involved in ROS regulation.  
 
Future Directions 
In this thesis it was established that HPV16 E6* is capable of inducing oxidative 
stress and DNA damage in both HPV+ and HPV- cells. One of the main molecular 
implications of this finding is the putative functional role of HPV16 E6* in increasing the 
frequency of HPV DNA integration. HPV DNA integration has been postulated as the 
main molecular step in converting a benign HPV infection into a malignant disease 
process such as cervical cancer. To date, few mechanisms for how HPV genome 
integration occurs in HPV-induced carcinogenesis have been proposed. Studies in W12 
cells demonstrated that increased DNA double-strand breaks are associated with HPV 16 
integration in cervical keratinocytes (D. M. Winder et al., 2007). Cells with integrated 
copies of HPV demonstrate increased proliferation and presumably form a pool of 
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immortalized cells within which further mutations can occur, sometimes leading to full 
transformation and cancer. Furthermore, the loss of E2 that occurs with integration allows 
the increased expression of E6 and E7, which also promotes genetic instability and the 
emergence of cancer.  
Because HPV integration is frequently a pivotal step in the process of HPV 
carcinogenesis, it is critical to determine the mechanisms by which HPV genes may 
facilitate this event. Ongoing experiments in our lab are focused on developing 
techniques that can be used to quantify HPV integration; these techniques will be used to 
answer this question. To begin identifying the mechanisms involved in these E6*-
mediated changes in oxidative stress, we identified some of the pathways involved in 
ROS regulation that may be influenced by HPV 16 E6 in CaSki and SiHa cells. However, 
to determine the individual effect of each of these isoforms on the previously identified 
pathways we plan to use the same NOK model system described in a chapter two, then 
perform experiments similar to those outlined in chapter three. Through the use of this 
model, we can then investigate the pathways involved in ROS metabolism that are 
influenced separately by the HPV 16 E6 and E6* isoforms.  
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